Issue number:
10/2013
Date Issued:
27 Aug 2013
Issued to:
Public and Private Hospitals and Private Pathology Laboratories
Purpose:
To advise of the listing of Subcutaneous Immunoglobulin (SCIg) under the national blood arrangements from 1 September 2013

Restriction

Subsidised SCIg under the national blood arrangements will only be approved for patients:

  • With a medical condition where there is support for use cited in the Criteria for the clinical use of intravenous immunoglobulin in Australia, namely:
    • Primary immunodeficiency diseases with antibody deficiency
    • Specific antibody deficiency
    • Acquired hypogammaglobulinaemia secondary to haematological malignancies (chronic lymphocytic leukaemia, multiple myeloma, non-Hodgkin lymphoma and other relevant malignancies, and post-haemopoietic stem cell transplantation
    • Secondary hypogammaglobulinaemia (including iatrogenic immunodeficiency), and
  • Who are being treated by a clinical specialist within a hospital based SCIg program, and
  • Following a patient-specific SCIg request submitted to and authorised by the Blood Service, available at http://www.transfusion.com.au/iTransfuse/resources/forms

Hospital based SCIg program

Hospitals wishing to access SCIg for their patients under the national blood arrangements are required to complete and send the form at:
http://www.blood.gov.au/subcutaneous-immunoglobulin to the Blood Service.

Administration and supply of SCIg

SCIg is a prescription only medication that may be used in an admitted patient or outpatient setting.
In the admitted patient setting, including day admitted, the medication may be administered by a nurse on the written instruction of a prescriber.
If SCIg is provided to a patient for out of hospital use it must be supplied by a medical practitioner or pharmacist in the lawful practice of their profession. Any such supply must be labelled in accordance with the provisions of regulation 29 of the Drugs, Poisons and Controlled Substances Regulations 2006 plus Appendix L of the Standard for the Uniform Scheduling of Medicines and Poisons and a record of the supply made.

Public patient charging for SCIg

  • Under the National Health Reform Agreement an eligible person receiving a public hospital service as a public patient will have no charges raised.
  • Non-admitted patients can be charged for surgical supplies such as syringes, swabs and other sundries the patient requires even though the SCIg is provided free of charge under the national blood arrangements.

National blood arrangements subsidised SCIg products

  • Evogam 0.8g/5mL and 3.2g/20mL
  • Gammanorm 1.6g/10mL and 3.3g/20mL
  • Kiovig 1g/10mL, 2.5g/25mL, 5g/50mL, 10g/100mL and 20g/200mL

Further Information

Any queries or questions related to this matter should be directed to: Michael Furey, Manager Blood and Pharmaceutical Programs: Michael.Furey@dhhs.vic.gov.au


Professor C W Brook
Executive Director
Wellbeing, Integrated Care and Ageing